Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2012 Mar 5;10(7):761–766.e1. doi: 10.1016/j.cgh.2012.02.027

Figure 2.

Figure 2

(A) Colonoscopy, mammography, and PAP smear incidence before and after the colonoscopy copay waiver in FY 2009 among women. A linear increasing trend in test use was observed for all tests. After the colonoscopy copay waiver, the observed vs expected test incidence was higher for colonoscopy (SIR, 1.20; 95% CI, 1.14–1.25), but not mammography (SIR, 0.94; 95% CI, 0.92–0.96) or PAP smear (SIR, 0.96; 95% CI, 0.94 – 0.98). (B) Colonoscopy and PSA incidence before and after the colonoscopy copay waiver in FY 2009 among men. A linear increasing trend in test use was observed for all tests. After the colonoscopy copay waiver, the observed vs expected test incidence was higher for colonoscopy (SIR, 1.17; 95% CI, 1.10–1.24), but not PSA (SIR, 0.95; 95% CI, 0.93–0.98).